Furegrelate sodium

SKU: orb1309656

Description

Furegrelate sodium (U-63557A) is an orally active, selective inhibitor of thromboxane A2 synthase, demonstrating potent activity with an IC50 of 15 nM in human platelet microsomes. It is a valuable research tool for investigating thromboxane-mediated pathways in cardiovascular, pulmonary, and thrombotic diseases, applicable in both in vitro and in vivo experimental models.

Research Area

Immunology & Inflammation, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 85666-17-7
• MW: 275.23
• Purity: 99.92% (May vary between batches)
• Formula: C₁₅H₁₀NNaO₃
• SMILES: C1=CC(=CN=C1)CC2=CC3=C(C=C2)OC(=C3)C(=O)[O-].[Na+]
• Target: PPAR,Others,Prostaglandin Receptor
• Solubility: DMSO:10 mg/mL (36.33 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (3.63 mM)

Bioactivity

• Target IC50:
  TXA2 receptor:15 nM
• In Vivo:
  Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.Furegrelate Sodium (1-5 mg/kg; Oral) prevents blockage of the coronary artery. Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation. Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

coronary, antiplatelet, available, arteries, arterial, Furegrelate, Furegrelate sodium, human, hypertension, Inhibitor, inhibit, orally, platelet, pulmonary, stenosed, U-63557A, TXA2R

Compound Identifiers

PubChem CID

23663954